Kelly Davio

Othman Al-Sawaf, MD, discusses findings from the CLL14 trial, the rationale for exploring this proposed combination, and shares his thoughts on the emerging treatment paradigms in chronic lymphocytic leukemia.

Naval G. Daver, MD, discusses the data that support quizartinib so far, ongoing investigations with this drug in the frontline setting, and the potential for the agent to be approved by the FDA.

Alfredo Addeo, MD, discusses the uniqueness of the 1-day Lung Cancer Summit and recent therapeutic advancements that have occurred in the lung cancer space.

Tony Mok, MD, discusses the KEYNOTE-042 trial and the implications of its findings, and sheds light on the evolving role of immunotherapy in non–small cell lung cancer.

Suresh S. Ramalingam, MD, describes findings with osimertinib, and discusses the emerging body of data exploring primary and acquired resistance mechanisms to the third-generation agent.

Bruno Sangro, MD, discussed the current landscape for systemic therapies, new directions with immunotherapy, and the need for greater research into combination therapies for patients with hepatocellular carcinoma.

Morris Sherman, MD, PhD, shared his insight on the news and discussions coming out of this year’s meeting, the surge of immunotherapy and targeted therapy research, optimal sequencing approaches, and the challenges that remain in treating patients with hepatocellular carcinoma.

Updates to the European Association for the Study of the Liver clinical guidelines introduce more opportunities for individual patient management of hepatocellular carcinoma.